In today's world, Carisbamate has become increasingly relevant. And, whether on a personal, professional or social level, Carisbamate has become a topic of common interest for a wide variety of people. The impact of Carisbamate is undeniable, since it affects aspects as diverse as the economy, technology, health, interpersonal relationships, and even the environment. For this reason, it is essential to thoroughly analyze the phenomenon of Carisbamate, its implications and its possible consequences in the short and long term. In this article, we will explore in detail all aspects related to Carisbamate, with the aim of providing a comprehensive and enriching vision on this topic that concerns us so much.
Clinical data | |
---|---|
Trade names | Comfyde (proposed) |
ATC code | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C9H10ClNO3 |
Molar mass | 215.63 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
Carisbamate (YKP 509, proposed trade name Comfyde) is an experimental anticonvulsant drug that was under development by Johnson & Johnson Pharmaceutical Research and Development but never marketed.
A phase II clinical trial in the treatment of partial seizures demonstrated that the compound has efficacy in the treatment of partial seizures and a good safety profile. Since late 2006, the compound has been undergoing a large multicenter phase III clinical trial for the treatment of partial seizures. Its mechanism of action is unknown.
A double-blind, placebo-controlled trial of carisbamate in 323 patients with migraine determined that carisbamate was well tolerated at doses up to 600 mg/day, but it failed to demonstrate that the drug was sufficiently more effective than placebo in migraine prophylaxis.
In 1998, the compound was in-licensed from SK Corp. (currently Life Science Business Division of SK Holdings), a South Korean company. On October 24, 2008, Johnson & Johnson announced that it had submitted a New Drug Application to the U.S. Food and Drug Administration (FDA) for carisbamate. Johnson & Johnson received provisional approval by the FDA to market carisbamate under the brand name of Comfyde. However, on August 21, 2009, Johnson & Johnson reported that the FDA had failed to give marketing approval.